63 related articles for article (PubMed ID: 22067666)
1. Measurement of mucosal biomarkers in a phase 1 trial of intravaginal 3% StarPharma LTD 7013 gel (VivaGel) to assess expanded safety.
Moscicki AB; Kaul R; Ma Y; Scott ME; Daud II; Bukusi EA; Shiboski S; Rebbapragada A; Huibner S; Cohen CR
J Acquir Immune Defic Syndr; 2012 Feb; 59(2):134-40. PubMed ID: 22067666
[TBL] [Abstract][Full Text] [Related]
2. Emerging concepts in dendrimer-based nanomedicine: from design principles to clinical applications.
Kannan RM; Nance E; Kannan S; Tomalia DA
J Intern Med; 2014 Dec; 276(6):579-617. PubMed ID: 24995512
[TBL] [Abstract][Full Text] [Related]
3. Two phase 3, double-blind, placebo-controlled studies of the efficacy and safety of Astodrimer 1% Gel for the treatment of bacterial vaginosis.
Chavoustie SE; Carter BA; Waldbaum AS; Donders GGG; Peters KH; Schwebke JR; Paull JRA; Price CF; Castellarnau A; McCloud P; Kinghorn GR
Eur J Obstet Gynecol Reprod Biol; 2020 Feb; 245():13-18. PubMed ID: 31812702
[TBL] [Abstract][Full Text] [Related]
4. A Brief History and Advancement of Contraceptive Multipurpose Prevention Technology (cMPT) Products.
Dohadwala S; Politch JA; Barmine JH; Anderson DJ
Open Access J Contracept; 2023; 14():83-94. PubMed ID: 37332341
[TBL] [Abstract][Full Text] [Related]
5. Dendrimer-Mediated Delivery of DNA and RNA Vaccines.
Kisakova LA; Apartsin EK; Nizolenko LF; Karpenko LI
Pharmaceutics; 2023 Mar; 15(4):. PubMed ID: 37111593
[TBL] [Abstract][Full Text] [Related]
6. Dendrimers, an Emerging Opportunity in Personalized Medicine?
Caminade AM
J Pers Med; 2022 Aug; 12(8):. PubMed ID: 36013283
[TBL] [Abstract][Full Text] [Related]
7. New synthetic procedure for the antiviral sulfonate carbosilane dendrimer G2-S16 and its fluorescein-labelled derivative for biological studies.
Gutiérrez-Ulloa C; Peña-González CE; Barrios-Gumiel A; Ceña-Díez R; Serramía-Lobera MJ; Muñoz-Fernández MÁ; Javier de la Mata F; Sánchez-Nieves J; Gómez R
RSC Adv; 2020 May; 10(34):20083-20088. PubMed ID: 35520432
[TBL] [Abstract][Full Text] [Related]
8. Baseline and time-updated factors in preclinical development of anionic dendrimers as successful anti-HIV-1 vaginal microbicides.
Rodríguez-Izquierdo I; Sepúlveda-Crespo D; Lasso JM; Resino S; Muñoz-Fernández MÁ
Wiley Interdiscip Rev Nanomed Nanobiotechnol; 2022 May; 14(3):e1774. PubMed ID: 35018739
[TBL] [Abstract][Full Text] [Related]
9. Emergence of Nanotechnology to Fight HIV Sexual Transmission: The Trip of G2-S16 Polyanionic Carbosilane Dendrimer to Possible Pre-Clinical Trials.
Relaño-Rodríguez I; Muñoz-Fernández MÁ
Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33321835
[TBL] [Abstract][Full Text] [Related]
10. Poly(N-vinylcaprolactam) Nanogels with Antiviral Behavior against HIV-1 Infection.
Macchione MA; Guerrero-Beltrán C; Rosso AP; Euti EM; Martinelli M; Strumia MC; Muñoz-Fernández MÁ
Sci Rep; 2019 Apr; 9(1):5732. PubMed ID: 30952921
[TBL] [Abstract][Full Text] [Related]
11. Pharmaceutical Vehicles for Vaginal and Rectal Administration of Anti-HIV Microbicide Nanosystems.
Mesquita L; Galante J; Nunes R; Sarmento B; das Neves J
Pharmaceutics; 2019 Mar; 11(3):. PubMed ID: 30917532
[TBL] [Abstract][Full Text] [Related]
12. The role of nanotechnology in the treatment of viral infections.
Singh L; Kruger HG; Maguire GEM; Govender T; Parboosing R
Ther Adv Infect Dis; 2017 Jul; 4(4):105-131. PubMed ID: 28748089
[TBL] [Abstract][Full Text] [Related]
13. Historical development of vaginal microbicides to prevent sexual transmission of HIV in women: from past failures to future hopes.
Notario-Pérez F; Ruiz-Caro R; Veiga-Ochoa MD
Drug Des Devel Ther; 2017; 11():1767-1787. PubMed ID: 28670111
[TBL] [Abstract][Full Text] [Related]
14. Nanomaterials in the Context of Type 2 Immune Responses-Fears and Potentials.
Himly M; Mills-Goodlet R; Geppert M; Duschl A
Front Immunol; 2017; 8():471. PubMed ID: 28487697
[TBL] [Abstract][Full Text] [Related]
15. Efficacy of HIV antiviral polyanionic carbosilane dendrimer G2-S16 in the presence of semen.
Ceña-Diez R; García-Broncano P; de la Mata FJ; Gómez R; Muñoz-Fernández MÁ
Int J Nanomedicine; 2016; 11():2443-50. PubMed ID: 27313457
[TBL] [Abstract][Full Text] [Related]
16. Immune Activation in the Female Genital Tract: Expression Profiles of Soluble Proteins in Women at High Risk for HIV Infection.
Francis SC; Hou Y; Baisley K; van de Wijgert J; Watson-Jones D; Ao TT; Herrera C; Maganja K; Andreasen A; Kapiga S; Coulton GR; Hayes RJ; Shattock RJ
PLoS One; 2016; 11(1):e0143109. PubMed ID: 26814891
[TBL] [Abstract][Full Text] [Related]
17. The potential of HIV-1 nanotherapeutics: from in vitro studies to clinical trials.
Roy U; Rodríguez J; Barber P; das Neves J; Sarmento B; Nair M
Nanomedicine (Lond); 2015; 10(24):3597-609. PubMed ID: 26400459
[TBL] [Abstract][Full Text] [Related]
18. Clinical Translation of Nanomedicine.
Min Y; Caster JM; Eblan MJ; Wang AZ
Chem Rev; 2015 Oct; 115(19):11147-90. PubMed ID: 26088284
[No Abstract] [Full Text] [Related]
19. Protein and oligonucleotide delivery systems for vaginal microbicides against viral STIs.
Steinbach JM
Cell Mol Life Sci; 2015 Feb; 72(3):469-503. PubMed ID: 25323132
[TBL] [Abstract][Full Text] [Related]
20. Nanoparticle-based drug delivery to the vagina: a review.
Ensign LM; Cone R; Hanes J
J Control Release; 2014 Sep; 190():500-14. PubMed ID: 24830303
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
